TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel and Oxaliplatin in Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Histologically proven gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction~* Metastatic or locally recurrent disease~* Prior adjuvant (and/or neo-adjuvant) chemotherapy with 5-Fluorouracil, Cisplatin, epirubicin is allowed provided that the patient has relapsed \> 12 months after the end of the chemotherapy~* Performance status Karnofsky index \> 70~* Hematology within 7 days before randomization:Hemoglobin ≥10g/dl, Absolute Neutrophil Count ≥2.0 10\^9/L, platelets ≥100 x 10\^9/L~* Blood chemistry within 7 days before randomization:Total bilirubin ≤1x Upper Normal Limit(UNL), Aspartate Aminotransferase (AST) Serum Glutamic Oxaloacetic Transaminase SGOT) and Alanine Aminotransferase (ALT)Serum Glutamate Pyruvate Transaminase(SGPT) ≤2.5xUNL, alkaline phosphatase ≤ 5x UNL, provided that AST or ALT \> 1.5 x UNL is not associated with alkaline phosphatase \> 2.5 x UNL; creatinine ≤1.25x UNL or 1.25x UNL \< creatinine ≤1.5x UNL and calculated/measured creatinine clearance ≥60 ml/min)~* Measurable and/or evaluable metastatic disease~Exclusion criteria:~* Any prior palliative chemotherapy~* Neurosensory symptoms National Cancer Institute Common Toxicity Criteria for Adverse Events grade≥2~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TE (Taxotere and Eloxatin) (Type: EXPERIMENTAL): Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study.
- TEF (Taxotere, Eloxatin and 5-FU) (Type: EXPERIMENTAL): Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study.
- TEX (Taxotere, Eloxatin and Xeloda) (Type: EXPERIMENTAL): Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis~* Inadequate response to anticholinergic medication used to treat overactive bladder~Exclusion Criteria:~* History of evidence of pelvic or urologic abnormality~* Previous or current diagnosis of bladder or prostate cancer~* Urinary tract infection at time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): botulinum toxin Type A (200U)
- 2 (Type: EXPERIMENTAL): botulinum toxin Type A (300U)
- 3 (Type: OTHER): placebo; botulinum toxin Type A (200U)
- 4 (Type: OTHER): placebo; botulinum toxin Type A (300U)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 to 65 years of age.~* Weight\> 50 kg and \<95 kg inclusive~* For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day 1.~* For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner\[s\] become pregnant during the full duration of the study.~* Willing, committed, and able to return for all clinic visits and complete all study-related procedures.~* Able to read, understand and willing to sign the informed consent form.~Exclusion Criteria:~* Initiation of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to screening visit.~* Pregnant or breast-feeding females.~* Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the subject's participation in this study.~* Hospitalization for any reason within 60 days of screening.~* Known history of Human Immunodeficiency Virus (HIV) antibody; and/or positive Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the screening visit.~* Previous exposure to any therapeutic or investigational biological agent.~* History of alcohol or substance abuse within previous 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Dose 1 versus placebo
- Cohort 2 (Type: EXPERIMENTAL): Dose 2 versus placebo
- Cohort 3 (Type: EXPERIMENTAL): Dose 3 versus placebo
- Cohort 4 (Type: EXPERIMENTAL): Dose 4 versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Spin on the Interpretation of Results of Randomized Trials in the Field of Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~The evaluators participating in this study were as follows:~The corresponding authors of published RCTs in the field of cancer Experts of a French national grant in the field of cancer~-investigator of trials registered in clinicaltrials.gov

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- abstract with spin (Type: ACTIVE_COMPARATOR): 30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
- abstract without spin (Type: EXPERIMENTAL): The abstracts with spin were systematically rewritten without spin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease~* ER positive tumor ≥ 10%~* HER2 negative breast cancer by FISH or IHC~* Progression of advanced breast cancer on first or second line endocrine therapy for advanced breast cancer~* Paraffin-embedded tumor available for centralized assessment of biomarkers~* Measurable disease according to RECIST 1.1 (bone only disease is allowed only if measurable).~* Postmenopausal status~* Eastern Cooperative Oncology Group (ECOG) Performance status 0 -2~* Resolution of all acute toxic effects of prior therapy or surgical procedures to CTCAE grade \>1~* Adequate organ function~Exclusion Criteria:~* Unstable brain metastases~* Prior treatment with more than one line of CT or more than two lines of HT advanced breast cancer or any CDK inhibitor~* Current treatment with therapeutic doses of anticoagulant~* Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors / inducers, drugs that are predominantly metabolized by CYP3A with narrow therapeutic indices, drugs with the potential of prolonging QT interval~* Diagnosis of any secondary malignancy within the last 3 years~* Active inflammatory bowel disease or chronic diarrhea~* Known human immunodeficiency virus infection; active hepatitis C, active hepatitis B

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Palbociclib monoterapy
- Arm B (Type: EXPERIMENTAL): Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with thalassemia major with at least 6 years of age undergoing iron chelation therapy.~2. No anticipated changes in chelation regimen for the next 12 months~3. Completed and signed Informed Consent~Exclusion Criteria:~1. Pregnancy~2. Advanced class III/IV heart failure or LVEF \< 0.35% (by MRI)~3. Formal contra-indications to MRI (pacemakers, cerebral aneurysm metal clips, etc).~4. Advanced heart AV block

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Starch pill (Type: PLACEBO_COMPARATOR): Placebo
- Amlodipine (Type: EXPERIMENTAL): Amlodipine 5mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anaesthesia for Laparoscopic Sleeve Gastrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Morbid obese scheduled for sleeve gastrectomy.~Exclusion Criteria:~* Patients refusal and allergy to drugs used.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Intravenous anaesthesia (Type: OTHER): Propofol Dexmedetomidine Remifentanil
- Inhalation anaesthesia (Type: OTHER): Desflurane Remifentanil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants 6 -12 weeks old at Dose 1 with written informed consent.~Exclusion Criteria:~* Allergic reaction to vaccine components;~* clinically significant history of chronic GI disease (uncorrected GI congenital malformation) or other serious medical condition per investigator, received vaccines or treatment prohibited by the protocol;~* immunocompromised.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 16 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women ≥ 18 years old~2. Histologically or cytologically confirmed diagnosis of breast cancer~3. Naïve patients~4. Be scheduled to receive adjuvant chemotherapy with anthracycline (doxorubicin or epirubicin) + cyclophosphamide (AC-based regimen)~5. ECOG (Eastern Cooperative Oncology Group) performance status 0-2~6. Body Mass index (BMI) ≥ 18.5~7. Written informed consent~8. If women of childbearing potential age: reliable contraceptive measures must be used during the study treatment period and up to 30 days after last NEPA administration~9. Acceptable hepatic function (\<= 2 times the upper limit of normal for liver transaminases) and renal function (creatinine \< 1.5 times the upper limit of normal);~10. Ability and willingness of the patient to complete the diary.~Exclusion Criteria:~1. Advanced/metastatic breast cancer~2. Patients already submitted to non-AC-based chemotherapy~3. Treatment with investigational medications in 30 days before NEPA~4. Myocardial infarction within the last 6 months~5. Documented or known hypersensitivity to 5HT3RA (5-Hydroxytryptamine Receptor 3 Antagonists) or NK1RA (Neurokinin-1 Receptor Antagonists) and excipients~6. Uncontrolled diabetes mellitus~7. Nausea and vomiting at baseline~8. Chronic use of other antiemetic agent(s)~9. Patient's inability to take oral medication~10. Gastrointestinal obstruction or active peptic ulcer~11. Pregnancy or breastfeeding~12. Prior malignancies at other sites except surgically treated non-melanoma skin cancer, superficial cervical cancer, or other cancer from which the patient had been disease-free for ≥ 5 years~13. Psychiatric or CNS (Central Nervous System) disorders interfering with ability to comply with study protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netupitant/Palonosetron & Dexamethasone (Type: EXPERIMENTAL): * Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.~* Dexamethasone 12 mg will be added on day 1 only of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study In Adults With Moderate To Severe Dermatomyositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for Patients with Skin Predominant Activity:~* Must have CDASI Activity score of greater than or equal to 14, and have failed at least 1 standard of care systemic treatment, (eg, corticosteroids).~* Confirmation of DM by the investigator and two of the following:~  1. Gottron's papules;~ 2. Gottron's sign;~ 3. Heliotrope eruption;~ 4. Nailfold changes, (dilated capillary loops, capillary dropout, cuticular hypertrophy and/or rugged cuticles;~ 5. Photodistributed violaceous erythema, (skin that is exposed to sunlight and appears purplish/reddish, and patchy in appearance;~ 6. Positive DM serology -~* Post DM diagnosis; standard of care workup for DM must have been completed prior to entry into this research study.~* Willing to provide 8 biopsies during the course of the research study~Inclusion Criteria for Patients with Muscle Predominant Activity:~* MMT-8 ≤136/150 and PhGA, VAS ≥3 cm (0-10 cm) by visual analog scale (VAS)~* Sum of PhGA, VAS, PtGA, and extramuscular global assessment VAS scores is ≥10 cm (0-10 cm) VAS for each.~  * Participant has failed at least two or more adequate courses of an immunosuppressive agent or immunomodulatory agent, including IVIG, at a dose known to be effective for rheumatologic diseases.~Exclusion Criteria for Patients with Skin Predominant Activity:~* Investigator site staff or members of their family.~* Acute and Chronic present medical conditions~* Intake of greater than 15 mg of prednisone or equivalent per day~* Pregnant or breastfeeding females. Fertile men and women who will not comply with the use of 2 effective birth control methods as per the research protocol~* Have required management of acute or chronic infections~* Have pre existing demyelinating disorder such as multiple sclerosis, or other severe neurological deficits.~* Clinically significant lab abnormalities~* Any health condition that may be worsened by immunosuppression~Exclusion Criteria for Patients with Muscle Predominant Activity:~Similar to patients with skin predominant activity; Intake of \>20 mg oral prednisone/day, or equivalent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo ARM (Type: PLACEBO_COMPARATOR): None
- PF-06823859 ARM high (Type: EXPERIMENTAL): None
- PF-06823859 ARM low (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: - Previous enrollment in Immunex protocol 016.0012.~* No clinically significant adverse events thought to be due to etanercept (TNFR:Fc) during previous treatment.~* Negative serum pregnancy test not more than 14 days before the first dose of study drug in females of childbearing potential.~* No more than one NSAID at a dose not greater than the maximum recommended dose and stable for at least two weeks prior to administration of etanercept (TNFR:Fc). Exclusion Criteria:~* Previous receipt of etanercept (TNFR:Fc) (p55), antibody to TNF, anti-CD4 antibody, or diphtheria IL-2 fusion protein.~* Receipt of investigational drugs or biologics (other than etanercept (TNFR:Fc)) within interval between study drug in 016.0012 and this study.~* Receipt of DMARDs (e.g., hydroxychloroquine, oral or injectable gold, azathioprine, cyclosporin, D-penicillamine, sulfasalazine, minocycline, or leflunomide) other than MTX within two weeks prior to the first dose of etanercept (TNFR:Fc) in this study.~* Receipt of cyclophosphamide within 1 month prior to the first dose of etanercept (TNFR:Fc) in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Genetic Polymorphisms on Ventricular Structure and Function in Patients With Single Ventricle Anatomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children who currently have functional single ventricle anatomy or have had heart transplantation for single ventricle anatomy who receive their cardiac care at Children's Healthcare of Atlanta, Egleston Hospital.~* Family agrees to participate in the study following informed consent~Exclusion Criteria:~* Conversion to two ventricle physiology, excluding transplantation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior to study entry~* Urinary incontinence in the 1-hour pad weight test exceeds 2.0 g~* The average number of SUI episodes is 1 or more per day~* The average number of urge urinary incontinence (UUI) episodes is 0.43 or less per day~* The number of SUI episodes exceeds the number of other episodes~* The average number of urinary diurnal frequency is 10 or less per day and the average number of nocturia frequency is 2 or less per day~Key Exclusion Criteria:~* Patient has been diagnosed with mixed urinary incontinence (MUI) that is predominantly UUI~* Patient has treated medication or therapy for SUI within 14 days before prior to study entry~* Patient is considered to have SUI that would not be expected to improve unless treated with surgical therapy~* Patient had a history of surgical treatment for urinary incontinence (Trans-obturator tape surgery, Tension-free vaginal tape surgery, etc.)~* Patient has stage II or more of Pelvic Organ Prolapse (POP), or had a history of POP repair surgery within 180 days before prior to study entry~* Patient has a serious illness or medical condition

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAS-303 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete